Kelun-Biotech Wins NMPA IND Nod for ITGB6-Targeted ADC SKB105 and Advances Oncology Collaboration With Crescent
I'm PortAI, I can summarize articles.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received Investigational New Drug approval from China's NMPA for SKB105, an integrin beta-6-targeted antibody-drug conjugate for advanced solid tumors. The company is advancing its oncology collaboration with Crescent Biopharma, which holds ex-China rights to SKB105 while Kelun retains Greater China rights. The latest analyst rating for Kelun's stock (HK:6990) is a Buy with a price target of HK$545.00, reflecting positive market sentiment towards the company's oncology portfolio and growth strategy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments